jun qi
Assistant Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (9)
Selective degradation of a disease‐associated protein of interest (POI) is a powerful therapeutic strategy. FDA‐approved and investigational glue and degrader drugs function by recruiting a POI to an E3 ubiquitin ligase that mediates POI polyubiquitination and triggers proteasomal degradation. However, using E3 ligases as an intermediary and requiring POI polyubiquitination makes this mechanism of action complex and difficult to rationalize and optimize. These issues have led to interest in evaluating whether direct recruitment of non‐ubiquitinated POIs to the proteasome might achieve the same pharmacological outcome. Here, we examined the potential of direct‐to‐proteasome non‐ubiquitinated POI recruitment. Using a tag strategy, we first demonstrated that the proteasomal 19S cap region proteins, RPN13 and RPN1, can recruit non‐ubiquitinated POI model proteins, such as BRD4, to the proteasome and induce degradation. Subsequently, we developed small molecule‐based bifunctional recruiter molecules (Proteasome Cap Targeting Chimeras, CAP‐TACs) and showed that they recruit several distinct POIs, including BRD4, PRMT5, and FKBP12, to specific subunits in the 19S cap region and induce their ubiquitination‐independent, proteasome‐dependent degradation. This study provides further evidence that bifunctional small molecules can re‐localize POIs to the proteasome and induce their degradation in the absence of ubiquitination, which broadens the capabilities of targeted protein degradation.
Year:
2026
Supplementary Table S1. List of SsTOP genes Supplementary Table S2. List of SsTOP (-E2F) genes Supplementary Table S3A. TF activity DMSO vs PKAi Supplementary Table S3B. TF activity PKAi+SIKi (COMBO) vs PKAi Supplementary Table S3A. CRTC2 targets gene set Supplementary Table S4. Curated FLC gene sets Supplementary Table S5. Expression of amino acid metabolism/urea cycle genes in FLC Supplementary Table S6. Regulation of curated FLC pathways by PKAi and SIKi in FLX1 Supplementary Table S7. MSigDB (Human) Hallark_E2F targets gene set
Year:
2025
Supplementary Figure S1: Validation of the specificity of the p-SIK Ser343 antibody. Supplementary Figure S2. PKAfus inactivates SIKs to support tumor cell growth in vitro and in vivo . Supplementary Figure S3. PKAfus reprograms transcription by inactivating SIK and stimulating CRTC2. Supplementary Figure S4. CRTC2/CREB mediates transcriptional regulation downstream of PKAfu. Supplementary Figure S5. CRTC2/CREB supports tumor cell growth downstream of PKAfus. Supplementary Figure S6. Primary FLC tumors show deregulation of SIK/CRTC2- controlled genes. Supplementary Figure S7. PKAfus driven tumors are sensitive to p300 inhibition. Supplementary Figure S8. PKAfus driven tumors are sensitive to p300 inhibition.
Year:
2025
Fibrolamellar carcinoma (FLC) is a liver cancer of adolescents and young adults characterized by fusions of the genes encoding the protein kinase A catalytic subunit, PRKACA, and heat shock protein, DNAJB1. The chimeric DNAJB1-PRKACA protein has increased kinase activity and is essential for FLC xenograft growth. Here, we explore the critical oncogenic pathways controlled by DNAJB1-PRKACA using patient-derived FLC models, engineered systems, and patient samples. We show that a core function of DNAJB1-PRKACA is the phosphorylation and inactivation of salt-inducible kinases (SIKs). This leads to deregulation of the CRTC2 transcriptional coactivator and p300 acetyltransferase, resulting in transcriptional reprogramming and increased global histone acetylation, driving malignant growth. Our studies establish a central oncogenic mechanism of DNAJB1-PRKACA and suggest the potential of targeting CRTC2/p300 in FLC. Notably, these findings link this rare cancer’s signature fusion oncoprotein to more common cancer gene alterations involving STK11 and GNAS, which also function via SIK suppression. Significance: This work combines functional studies in model systems and examination of human tumor specimens to define a central oncogenic pathway driven by DNAJB1-PRKACA fusions in FLC. DNAJB1-PRKACA-mediated inactivation of the SIK stimulates CRTC2-p300-mediated transcription to drive tumor growth. The findings illuminate pathogenic mechanisms and inform therapeutic development.
Year:
2025
Supplementary Table S1. List of SsTOP genes Supplementary Table S2. List of SsTOP (-E2F) genes Supplementary Table S3A. TF activity DMSO vs PKAi Supplementary Table S3B. TF activity PKAi+SIKi (COMBO) vs PKAi Supplementary Table S3A. CRTC2 targets gene set Supplementary Table S4. Curated FLC gene sets Supplementary Table S5. Expression of amino acid metabolism/urea cycle genes in FLC Supplementary Table S6. Regulation of curated FLC pathways by PKAi and SIKi in FLX1 Supplementary Table S7. MSigDB (Human) Hallark_E2F targets gene set
Year:
2025
Supplementary Figure S1: Validation of the specificity of the p-SIK Ser343 antibody. Supplementary Figure S2. PKAfus inactivates SIKs to support tumor cell growth in vitro and in vivo . Supplementary Figure S3. PKAfus reprograms transcription by inactivating SIK and stimulating CRTC2. Supplementary Figure S4. CRTC2/CREB mediates transcriptional regulation downstream of PKAfu. Supplementary Figure S5. CRTC2/CREB supports tumor cell growth downstream of PKAfus. Supplementary Figure S6. Primary FLC tumors show deregulation of SIK/CRTC2- controlled genes. Supplementary Figure S7. PKAfus driven tumors are sensitive to p300 inhibition. Supplementary Figure S8. PKAfus driven tumors are sensitive to p300 inhibition.
Year:
2025
Purpose: BRD9 is a defining component of the noncanonical SWI/SNF complex, which regulates gene expression by controlling chromatin dynamics. Although recent studies have found an oncogenic role for BRD9 in multiple cancer types including multiple myeloma, its clinical significance and oncogenic mechanism have not yet been elucidated. Here, we sought to identify the clinical and biological impact of BRD9 in multiple myeloma, which may contribute to the development of novel therapeutic strategies. Experimental Design: We performed integrated analyses of BRD9 in vitro and in vivo using multiple myeloma cell lines and primary multiple myeloma cells in established preclinical models, which identified the molecular functions of BRD9 contributing to multiple myeloma cell survival. Results: We found that high BRD9 expression was a poor prognostic factor in multiple myeloma. Depleting BRD9 by genetic (shRNA) and pharmacologic (dBRD9-A; proteolysis-targeting chimera; BRD9 degrader) approaches downregulated ribosome biogenesis genes, decreased the expression of the master regulator MYC, and disrupted the protein-synthesis maintenance machinery, thereby inhibiting multiple myeloma cell growth in vitro and in vivo in preclinical models. Importantly, we identified that the expression of ribosome biogenesis genes was associated with the disease progression and prognosis of patients with multiple myeloma. Our results suggest that BRD9 promotes gene expression by predominantly occupying the promoter regions of ribosome biogenesis genes and cooperating with BRD4 to enhance the transcriptional function of MYC. Conclusions: Our study identifies and validates BRD9 as a novel therapeutic target in preclinical models of multiple myeloma, which provides the framework for the clinical evaluation of BRD9 degraders to improve patient outcome.
Year:
2025
Dysregulated epigenetic programs that restrict differentiation, reactivate fetal genes, and confer phenotypic plasticity are critical to colorectal cancer (CRC) development. By screening a small molecule library targeting epigenetic regulators using our dual reporter system, we found that inhibiting histone deacetylase (HDAC) 1/2 promotes CRC differentiation and anti-tumor activity. Comprehensive biochemical, chemical, and genetic experiments revealed that on-target blockade of the HDAC1/2 catalytic domain mediated the differentiated phenotype. Unbiased profiling of histone posttranslational modifications induced by HDAC1/2 inhibition nominated acetylation of specific histone lysine residues as potential regulators of differentiation. Genome-wide assessment of implicated marks indicated that H3K27ac gains at HDAC1/2-bound regions associated with open chromatin and upregulation of differentiation genes upon HDAC1/2 inhibition. Disrupting H3K27ac by degrading acetyltransferase EP300 rescued HDAC1/2 inhibitor-mediated differentiation of a patient-derived CRC model using single cell RNA-sequencing. Genetic screens revealed that DAPK3 contributes to CRC differentiation induced by HDAC1/2 inhibition. These results highlight the importance of specific chemically targetable histone modifications in governing cancer cell states and epigenetic reprogramming as a therapeutic strategy in CRC. BRIEF SUMMARY HDAC1/2 inhibition promotes colorectal cancer differentiation via gains in H3K27ac, which can be reversed by blocking its acetyltransferase EP300.
Year:
2024
Purpose: BRD9 is a defining component of the noncanonical SWI/SNF complex, which regulates gene expression by controlling chromatin dynamics. Although recent studies have found an oncogenic role for BRD9 in multiple cancer types including multiple myeloma, its clinical significance and oncogenic mechanism have not yet been elucidated. Here, we sought to identify the clinical and biological impact of BRD9 in multiple myeloma, which may contribute to the development of novel therapeutic strategies. Experimental Design: We performed integrated analyses of BRD9 in vitro and in vivo using multiple myeloma cell lines and primary multiple myeloma cells in established preclinical models, which identified the molecular functions of BRD9 contributing to multiple myeloma cell survival. Results: We found that high BRD9 expression was a poor prognostic factor in multiple myeloma. Depleting BRD9 by genetic (shRNA) and pharmacologic (dBRD9-A; proteolysis-targeting chimera; BRD9 degrader) approaches downregulated ribosome biogenesis genes, decreased the expression of the master regulator MYC, and disrupted the protein-synthesis maintenance machinery, thereby inhibiting multiple myeloma cell growth in vitro and in vivo in preclinical models. Importantly, we identified that the expression of ribosome biogenesis genes was associated with the disease progression and prognosis of patients with multiple myeloma. Our results suggest that BRD9 promotes gene expression by predominantly occupying the promoter regions of ribosome biogenesis genes and cooperating with BRD4 to enhance the transcriptional function of MYC. Conclusions: Our study identifies and validates BRD9 as a novel therapeutic target in preclinical models of multiple myeloma, which provides the framework for the clinical evaluation of BRD9 degraders to improve patient outcome.
Year:
2024
Collaborators (11)
Robert Manguso
Associate Professor
Harvard Medical School
Tenna Holgersen Bryde
Københavns Universitet
Taran Gujral
Professor
Fred Hutchinson Cancer Research Center
Marc Wein
Associate Professor of Medicine
Massachusetts General Hospital
Kei Sakamoto
Professor at University of Copenhagen
University of Copenhagen
John D. Gordan
University of California
Eugenio Morelli
Assistant Professor
Università degli Studi di Torino
Meng-Ju Wu
Assistant Professor
University of Massachusetts Chan Medical School
Mehmet Samur
Senior Research Scientist
Dana-Farber Cancer Institute
David Liu
Assistant Professor
Dana-Farber Cancer Institute
Annamaria Gulla
Group leader
Candiolo Cancer Institute, FPO-IRCCS
Make your next move.
Prepare your application
Review drafts before you send them.